Human EGFR Monoclonal Antibody, Endotoxin 0.05 EU/mg (YR0026)

Basic Information

Clone	Cetuximab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<0.05EU/mg (<0.00005EU/μg) Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.

Immunogen Information

Isotype	Human IgG1 kappa
Immunogen	Human EGFR
RecommendedIsotype Control(s)	In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer	1×PBS pH 7.0

* For research use only. Not for therapeutic or diagnostic purposes.